0001671352-21-000002.txt : 20210205 0001671352-21-000002.hdr.sgml : 20210205 20210205100138 ACCESSION NUMBER: 0001671352-21-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210205 DATE AS OF CHANGE: 20210205 EFFECTIVENESS DATE: 20210205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WindMIL Therapeutics, Inc. CENTRAL INDEX KEY: 0001671352 IRS NUMBER: 475618887 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-388545 FILM NUMBER: 21594357 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 4105581906 MAIL ADDRESS: STREET 1: 3675 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19104 D 1 primary_doc.xml X0708 D LIVE 0001671352 WindMIL Therapeutics, Inc. 3675 MARKET STREET SUITE 200 PHILADELPHIA PA PENNSYLVANIA 19104 4105581906 DELAWARE None None Corporation true Donald J. Hayden, Jr. c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Executive Officer Director Brian Dovey c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Director Anna French c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Director Mark McDade c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Director Daniel O'Donnell c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Director Howard Soule c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Director Patrick Fabbio c/o WindMIL Therapeutics, Inc. 3675 Market Street, Suite 200 Philadelphia PA PENNSYLVANIA 19104 Executive Officer Biotechnology Decline to Disclose 06b false 2021-01-26 false true true false 0 5000000 2334814 2665186 The total offering amount of $5,000,000 will be sold in two tranches. The first tranche equal to $2,334,814.78 of the total offering amount was sold on January 26, 2021. The remaining tranche will be sold upon the occurrence of certain events. false 11 0 0 0 false WindMIL Therapeutics, Inc. /s/ Donald J. Hayden, Jr. Donald J. Hayden, Jr. Chief Executive Officer 2021-02-05